Aprocitentan in Patients With CKD and Resistant Hypertension ca. 2026
#Nephpearls #NephSky
✅ Well tolerated
✅ Lowered BP (nighttime ambulatory BP)
✅ Markedly reduced urine albumin-to-creatinine ratio (UACR) in participants w/ CKD and resistant hypertension
👉 pubmed.ncbi.nlm.nih.gov/41363010/
Mechanisms by which novel antihypertensive drug classes reduce blood pressure ca. 2025 from @natrevcardiol.nature.com
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/39920248/
C3 glomerulopathy in transplant “like yet unlike native”: Pathophysiology, recent advances in therapeutics and evolving paradigms ca. 2026 @saynanorouzi.bsky.social
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/42281853/
Guideline for Prevention, Detection, Evaluation, & Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome ca. 2026 from @americanheart.bsky.social @accintouch.bsky.social @amdiabetesassn.bsky.social @asnkidney.bsky.social
#Nephpearls #Cardiorenal #NephSky
👉 pubmed.ncbi.nlm.nih.gov/42265997/
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Edgar V. Lerma 🇵🇭
Hyperkalemia and Its Treatment: Real-World Evidence and Managed Care Considerations Supporting Use of Potassium Binders ca. 2026 from @beaverspharmd.bsky.social
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/42213908/
Consensus Recommendation: Real World Insights on Attitudes and Treatment of Hyperkalemia ca. 2026 from @garysinger.bsky.social @renalphysicians.bsky.social
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/42069178/
Hyperkalemia and Its Treatment: Real-World Evidence and Managed Care Considerations Supporting Use of Potassium Binders ca. 2026 from @beaverspharmd.bsky.social
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/42213908/
Treatment of chronic hyponatremia from Dr Ewout Hoorn
#Nephpearls #ERA26 #NephSky
Hemodynamic monitoring in in ICU: Capillary refill time (CRT), is quick, easily performed, and a long-standing component of the physical exam
#Nephpearls #AKIinICU #NephSky
👉 pubmed.ncbi.nlm.nih.gov/30772908/
👉 www.wolterskluwer.com/en/solutions...
FIND-CKD: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months ca. 2026 from @nejm.org
#Nephpearls #ERA26 #NephSky
👉 www.nejm.org/doi/full/10....
